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        Prostaglandins, prostaglandin E2 (PGE2) in par-
ticular, play an important role in the regula-
tion of infl  ammatory responses. PGE2 is a key 
mediator of pyrexia, hyperalgesia, and arterial 
dilation, which increases blood fl  ow to infl  amed 
tissues and, in combination with enhanced mi-
crovascular permeability, results in edema. The 
relevance of this pathway in promoting in-
fl  ammation is supported by the clinical use of 
cyclooxygenase inhibitors, which interfere with 
prostaglandin synthesis and are used as eff  ective 
antiinfl  ammatory agents (  1  ). However, PGE2 
can also exert antiinfl  ammatory properties and 
is a negative regulator of neutrophil, monocyte, 
and lymphocyte function, particularly of Th1 
cells that produce IFN-      (  2  ). This apparent 
paradox has puzzled many investigators for de-
cades. The interplay among PGE2, IL-23, and 
IL-1      biology may now provide an explanation 
of this paradox. 
  Th17 cells have been recognized as a unique 
subset of eff  ector T cells that are distinct from 
the Th1 and Th2 subsets (  3  –  6  ), and they have 
been implicated as potent eff  ectors of auto-
immune disorders, such as multiple sclerosis, 
psoriasis, arthritis, and infl  ammatory bowel dis-
ease (IBD) (  7  –  10  ). We and others have previ-
ously reported that IL-23 and IL-1      are crucial 
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  Prostaglandins, particularly prostaglandin E2 (PGE2), play an important role during infl  am-
mation. This is exemplifi  ed by the clinical use of cyclooxygenase 2 inhibitors, which inter-
fere with PGE2 synthesis, as effective antiinfl  ammatory drugs. Here, we show that PGE2 
directly promotes differentiation and proinfl  ammatory functions of human and murine 
IL-17  –  producing T helper (Th17) cells. In human purifi  ed naive T cells, PGE2 acts via prosta-
glandin receptor EP2- and EP4-mediated signaling and cyclic AMP pathways to up-regulate 
IL-23 and IL-1 receptor expression. Furthermore, PGE2 synergizes with IL-1     and IL-23 to 
drive retinoic acid receptor  –  related orphan receptor (ROR)-    t, IL-17, IL-17F, CCL20, and 
CCR6 expression, which is consistent with the reported Th17 phenotype. While enhancing 
Th17 cytokine expression mainly through EP2, PGE2 differentially regulates interferon 
(IFN)-     production and inhibits production of the antiinfl  ammatory cytokine IL-10 in Th17 
cells predominantly through EP4. Furthermore, PGE2 is required for IL-17 production in the 
presence of antigen-presenting cells. Hence, the combination of infl  ammatory cytokines 
and noncytokine immunomodulators, such as PGE2, during differentiation and activation 
determines the ultimate phenotype of Th17 cells. These fi  ndings, together with the altered 
IL-12/IL-23 balance induced by PGE2 in dendritic cells, further highlight the crucial role of 
the infl  ammatory microenvironment in Th17 cell development and regulation. 
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conditions.   EP1   and   EP3   mRNA levels remained low after 
activation and culture under these same conditions. These 
results indicate that EP2 and EP4 constitute the major PGE2 
receptors on naive and activated T cells. 
  IL-23 and IL-1      have been shown to drive the develop-
ment of human Th17 cells, which are characterized by a spe-
cifi  c signature cytokine profi  le consisting of IL-17, IL-17F, 
IL-22, CCL20/MIP3     , and IFN-      (  9, 11, 12  ). To investigate 
a potential role of PGE2 in Th17 diff  erentiation, we next ex-
amined the eff  ects of PGE2 on the expression of IL-23 and 
IL-1 receptors. Interestingly, activation and culture of naive 
T cells in the presence of PGE2 resulted in a strong and 
reproducible up-regulation of IL-23R expression (  Fig. 1, 
C and D  ).   IL-1R1   gene expression was also increased in re-
sponse to PGE2 (  Fig. 1 E  ). Butaprost, an EP2 selective ago-
nist, and misoprostol, a nonselective agonist with the highest 
affi   nity for EP4 and EP3, increased IL-23R expression com-
parable to PGE2. In contrast, the EP1/EP3 agonist sulpros-
tone had no eff  ect (  Fig. 1 F  ), indicating that the eff  ects of 
PGE2 on IL-23R expression were specifi  cally mediated 
through EP2 and EP4 receptors. The addition of the intracel-
lular cAMP analogue dibutyryl-cAMP mimicked the eff  ect 
of PGE2 on IL-23R expression (  Fig. 1 G  ), suggesting that 
the eff  ect of PGE2 was dependent on cAMP formation. 
These results suggest a mechanism by which PGE2 could af-
fect the Th17 pathway through up-regulation of IL-23 and 
IL-1 receptor expression. 
  PGE2 promotes development of human Th17 cells 
  As PGE2 enhanced both IL-23 and IL-1      receptor expression 
from activated naive T cells, we determined whether PGE2 
could modulate the eff  ects of IL-1      and IL-23 during the de-
velopment of Th17 cells. Activation and culture of naive 
T cells with PGE2 alone slightly increased IL-17 production in 
few donors (  Fig. 2 A  ).   However, PGE2 signifi  cantly enhanced 
IL-17 production induced by IL-23 and/or IL-1      (  Fig. 2 A  ). 
The combination of IL-23, IL-1     , and PGE2 (IL-23  –  IL-1       –
  PGE2) did not lead to further increase in IL-17 production 
over that induced by PGE2 and IL-1     . The addition of IL-23 to 
IL-23  –  IL-1       –  PGE2  –  treated cells compared with IL-23  –  IL-1      
cultures resulted in an enhanced phosphorylation of STAT3, 
which is in line with the up-regulated expression of IL-23R in 
the presence of PGE2 (Fig. S2 B), and indicates that the en-
hanced IL-23R expression is functional. The increase in IL-17 
production induced by IL-1      and IL-23 in response to PGE2 
was dose dependent (Fig. S2 C). In addition, the proportion of 
IL-17  +   and IL-17  +  /IFN-       +   producers was increased in IL-23  –
  IL-1       –  PGE2 cultures compared with IL-23  –  IL-1       –  treated 
cells, whereas IFN-      single producers were present at similar 
levels (Fig. S2 D). Furthermore, the increased IL-17 produc-
tion was more strongly controlled by EP2 than EP4 signaling 
because the EP2 agonist butaprost could mimic the eff  ect of 
PGE2 to a similar extent, whereas misoprostol was not able to 
induce such a strong induction of IL-17 production (  Fig. 2 B  ). 
The increase in IL-17 secretion mediated through activation of 
the cAMP pathway was consistent with the observed EP2 or 
factors during development of human Th17 cells (  9, 11, 12  ). 
In addition, IL-23 and the IL-23  –  dependent Th17 cell popu-
lation play essential roles in chronic infl  ammation and auto-
immunity (  13  ). 
  PGE2 has been shown to exacerbate infl  ammation and 
disease severity in murine models of IBD and collagen-induced 
arthritis through the IL-23  –  IL-17 pathway (  14, 15  ). These ef-
fects have been attributed to actions of PGE2 on innate cells, as 
PGE2 enhances the production of IL-23 and IL-1      in macro-
phages and DCs, while down-regulating IL-12 production (  16  ). 
A recent report has shown that PGE2, together with IL-23, 
favors the expansion of human Th17 cells from PBMCs, and 
that PGE2 enhances IL-17 production induced by IL-23 from 
memory CD4  +   cells (  17  ). However, the molecular mecha-
nism of PGE2-mediated signaling during human Th17 cell 
development has not yet been examined. 
  In this study, we show that PGE2 acts directly on both 
human and murine T cells to enhance Th17 development 
and eff  ector cytokine production. In human T cells, PGE2 
acts via the prostaglandin receptor EP2- and EP4-mediated 
signaling and cAMP pathways to up-regulate IL-23 and IL-1 
receptor expression. Furthermore, PGE2 synergizes with IL-1      
and IL-23 to drive retinoic acid receptor  –  related orphan 
receptor (ROR)-     t, IL-17, IL-17F, CCL20, and CCR6 ex-
pression, which is consistent with the previously reported 
Th17 phenotype (  8, 18  ). While enhancing Th17 cytokine 
expression mainly through EP2, PGE2 diff  erentially regulates 
IFN-      production and inhibits production of the antiinfl  am-
matory cytokine IL-10 in both naive and memory Th17 cells 
predominantly through EP4. Hence, the combination of in-
fl  ammatory cytokines and noncytokine immunomodulators, 
such as PGE2, during diff  erentiation and activation deter-
mines the ultimate phenotype of Th17 cells. These fi  ndings, 
together with the altered IL-12/IL-23 balance induced by 
PGE2 in dendritic cells, further highlight the crucial role of 
the infl  ammatory microenvironment in Th17 cell develop-
ment and regulation. 
    RESULTS   
  PGE2 up-regulates IL-23 and IL-1 receptor expression 
on naive T cells via EP2, EP4, and cAMP signaling 
  To study the eff  ects of PGE2 on T cells, we fi  rst analyzed the 
expression of the PGE2 receptors EP1, EP2, EP3, and EP4. 
Human naive CD4  +  CD45RA  +   T cells were isolated from 
peripheral blood of healthy donors, as previously described 
(  9  ). The purity of these naive T cell populations was routinely 
  >  99.5% (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20082293/DC1). Freshly isolated naive T cells con-
stitutively expressed high levels of   EP2   and   EP4   mRNA, 
whereas   EP1   and   EP3   mRNA expression was low or nonex-
istent (  Fig. 1 A  ).   Cell surface expression of EP2 and EP4 pro-
tein was confi  rmed by fl  ow cytometric analysis (  Fig. 1 B  ). 
Activation and culture of naive T cells led to a two- to three-
fold up-regulation of   EP2   and   EP4   transcripts (Fig. S2 A). 
This up-regulation was not aff  ected by the addition of Th1  –
  IL-12  –   or Th17  –  IL-23– and/or IL-1       –  polarizing culture JEM VOL. 206, March 16, 2009 
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A time course of   ROR    t   expression during T cell polar-
ization confi  rmed that after 11 d of culture, IL-23  –  IL-1       –
  PGE2–derived Th17 cells expressed higher levels of   ROR    t   
transcripts compared with IL-23  –  IL-1      control cultures (  Fig. 
2 D  ), which is in agreement with the up-regulated IL-17 
production by these cells. Th17 cells also produce IL-17F, 
IL-22, and CCL20/MIP3     . A similar profi  le of IL-23  –  IL-
1       –  PGE2  –  dependent regulation was observed for IL-17F 
EP4 signaling (  Fig. 2 C  ). The eff  ects of dibutyryl-cAMP 
on IL-17 production were consistent and dose dependent 
(Fig. S2 E). The diff  erential increase of IL-17 production in 
response to EP2 or EP4 may be caused by the more robust 
stimulation of intracellular cAMP formation by EP2 compared 
with EP4, as previously reported (  19  ). 
  The development of Th17 cells is dependent on the in-
duction of the Th17-specifi  c transcription factor   ROR    t   (  20  ). 
  Figure 1.       PGE2 up-regulates IL-23R and IL-1R1 expression on cultured human naive CD4  +   T cells.     (A  ) Real-time PCR analysis of   EP1 ,   EP2 ,   EP3 , 
and   EP4   gene expression in human naive CD4  +   T cells. Mean + SEM of eight donors. Relative amplifi  cation effi  ciencies of EP primer sets fell within stan-
dard Taqman assay specifi  cations. (  B  ) Isotype (gray) or EP2 and EP4 (black) surface staining. (  C    –    G  ) Naive CD4  +   T cells were activated with anti-CD3/CD28/
CD2 beads and cultured for 11 d in the presence or absence of PGE2, dibutyryl-cAMP, or specifi  c EP receptor agonists. (  C—D  ) Flow cytometric quantifi  ca-
tion of IL-23R in CD3  +   CD4 +   T cells restimulated for 48 h. (D) Box and whiskers of eight independent experiments are shown. **, P   <   0.01. (  E  ) Real-time 
PCR analysis of   IL-1R1   gene expression in T cells restimulated for 24 h. Results from six different donors are shown. *, P   <   0.05. (F and G) Flow cytometric 
quantifi  cation of IL-23R in CD3  +   CD4 +   T cells restimulated for 48 h. Mean + SEM of four independent experiments.     538 PGE2 MODULATES THE IL-23–TH17 CELL PATHWAY   | Boniface et al. 
eff  ects of PGE2 on T cells in the presence of APCs. Like T 
cells, human monocytes mainly expressed   EP2   and   EP4   tran-
scripts (  Fig. 3 A  ).   Activation of monocytes through the TLR2 
pathway by peptidoglycan resulted in the production of 
IL-23 and IL-1      (  Fig. 3 B  ). However, when monocytes 
were activated with PGE2 in the absence of TLR ligands or 
cytokines, we did not detect any IL-23 or IL-1      production 
(  Fig. 3 B  ). In line with these results, addition of PGE2 to 
co-culture of naive T cells with monocytes in the absence of 
exogenously added cytokines did not induce IL-17 produc-
tion. Interestingly, in the presence of monocytes, the combi-
nation of IL-23 and IL-1      failed to induce IL-17 production 
in most donors; however, addition of PGE2 overcame this 
suppressive eff  ect and resulted in IL-17 production (  Fig. 3 C  ). 
These results indicate that PGE2 was essential for IL-17 pro-
duction induced by IL-23 and IL-1      in this T cell–APC co-
culture system. 
and CCL20 expression (  Fig. 2 E, F  ). In contrast, IL-22 and 
IL-26 expression was decreased in the presence of PGE2 
alone; however, their expression was not altered by the addi-
tion of PGE2 to cultures containing IL-23 and IL-1      (  Fig. 2 G   
and Fig. S2 F). These results indicated that although IL-22 and 
IL-26 are an integral part of Th17 biology, their expression is 
subject to multiple levels of regulation. All the observations 
on Th17 cytokine production were confi  rmed at the level of 
gene expression (Fig. S2 F). These results thus indicate that 
PGE2 can act directly on naive T cells and enhance Th17 
development mainly through the EP2  –  cAMP pathway. 
  PGE2 induces IL-17 production in T cell  –  APC co-cultures 
  PGE2 pretreatment of APCs promotes Th17 diff  erentiation 
in mice by altering the IL-12/IL-23 balance (  14  –  16, 21  ). In 
addition, PGE2 enhanced IFN-      and TLR7 induced IL-23 
production (  22  ). It was therefore of interest to determine the 
  Figure 2.       PGE2, together with IL-1     and IL-23, enhances Th17 cell development predominantly via EP2 signaling and cAMP pathways.   Human 
naive CD4  +   T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-23, IL-1     , PGE2, dibutyryl-cAMP, and/or EP re-
ceptors agonists. (  A  –  C  ) IL-17 production in cell-free supernatants of T cells restimulated for 48 h. (D) Real-time PCR of   ROR  t   gene expression in T cells after 
indicated time of culture. (  E  –  G  ) IL-17F (E), CCL20 (F), and IL-22 (G) production in cell-free supernatants of T cells restimulated for 48 h. Data from six different 
donors are shown in A, E, F, and G; horizontal bars represent median values. Results in   B   show mean + SEM of three independent experiments. Data in   C   show 
mean + SEM of fi  ve independent experiments. Data in   D   are representative of two independent experiments. *, P   <   0.05; **, P   <   0.01.    JEM VOL. 206, March 16, 2009 
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combination of IL-1      and IL-23, PGE2 was not able to 
inhibit IFN-      secretion, indicating that PGE2 could not ef-
fectively interfere with the effi   cacy of the combined signal 
transduction pathways. Accordingly, PGE2 inhibited   T-bet   
mRNA expression in activated T cells diff  erentiated with 
either IL-1      or IL-23, whereas   T-bet   levels were only slightly 
reduced in IL-23  –  IL-1       –  PGE2–cultured cells (  Fig. 4 G  ). 
These results indicate that the ability of PGE2 to inhibit IFN-      
production is dependent on the maturation state of the T cells 
and cytokine milieu. Overall, these data indicate that PGE2 
modulates the Th17 phenotype to a high IL-17  –  , IL-17F  –  , 
CCL20-, low IFN-     –    , low IL-10  –  producing cell that could 
be more pathogenic. 
  PGE2 enhances maturation of developing Th17 cells 
  In addition to its eff  ects on cytokine and cytokine receptor 
expression, the combined activity of PGE2, IL-1     , and IL-23 
led to an enhanced maturation of developing Th17 cells. 
Memory Th17 cells isolated from human blood express 
CCR6 (  8, 18  ), the receptor for CCL20 and      -defensins. We 
observed that only the combined presence of IL-23, IL-1     , 
and PGE2 led to an enhanced up-regulation of CCR6 ex-
pression in naive T cells (  Fig. 5, A and B  ), as well as an in-
crease of CCR6  +  CCR4  +   and CCR6  +  IL-23R  +   cells (  Fig. 5, 
C and D  ).   CCR6 expressed by IL-23  –  , IL-1       –  , and PGE2-
treated T cells was functional, as CCR6  +   T cells, but not 
CCR6         T cells, had chemotactic activities in response to its 
ligand CCL20. Both T cell populations migrated equally well 
toward SDF1      (  Fig. 5 E  ), a ligand of CXCR4 that is ex-
pressed on T cells. Reactivation of sorted CCR6  +   T cells 
isolated from IL-23 –  IL-1       –  PGE2  –  driven Th17 cells revealed 
that   >  50% were IL-17  –  producing cells, whereas few IL-17 
producers were present in the CCR6         T cell population 
  PGE2 inhibits Th17 production of IL-10 and IFN-     
predominantly through EP4 signaling 
  Recent evidence suggests that IL-10 restrains the pathoge-
nicity of Th17 cells in mice (  23, 24  ), prompting us to also 
examine the production of IL-10 in human Th17 cells. IL-23, 
but not IL-1     , increased IL-10 production in activated naive 
T cell cultures (  Fig. 4 A  ).   IL-10 production remained below 
levels that were observed with IL-12 (unpublished data). 
Addition of PGE2 strongly suppressed the production of 
IL-10 in both control and Th17-inducing conditions (  Fig. 4 A  ). 
This eff  ect was mainly mediated through EP4 signaling as 
shown by the addition of the EP4 agonist misoprostol (  Fig. 
4 B  ). Interestingly, although dibutyryl-cAMP inhibited IL-10 
production in control cultures, it failed to down-regulate 
IL-10 production in IL-23  –  IL-1       –  treated cells (  Fig. 4 C  ), 
suggesting that additional signaling pathways are involved in 
response to PGE2 and EP4 stimulation (  19  ). These results 
further corroborate the fi  nding that down-regulation of the 
antiinfl  ammatory IL-10 pathway by PGE2 might further ex-
acerbate Th17-mediated infl  ammation. 
  PGE2 suppressed IFN-      production from activated naive 
T cells cultured in the absence of additional cytokines (  Fig. 
4 D  ), in accordance with the established dogma (  25  –  27  ). We 
previously reported that IL-23 enhanced IFN-      production 
by PHA blasts (  28  ) and that human Th17 cells, diff  erentiated 
in the presence of either IL-1      or IL-23, are able to produce 
IFN-      (  9  ). The production of IFN-      by Th17 cells diff  eren-
tiated by IL-1      or IL-23 was strongly inhibited by PGE2 
(  Fig. 4 D  ). The inhibitory eff  ect of PGE2 on IFN-      produc-
tion was predominantly mediated through EP4 signaling 
  because it could be mimicked by the addition of the EP4 
  agonist misoprostol (  Fig. 4 E  ) and through elevation of cAMP 
(  Fig. 4 F  ). However, when Th17 cells were generated by the 
  Figure 3.       PGE2 is required for IL-23  –  IL-1      –  induced IL-17 production in a monocyte-naive T cell co-culture system.   (A) Real-time PCR analy-
sis of   EP1 ,   EP2 ,   EP3  , and   EP4   gene expression in human CD14  +   monocytes. Mean + SEM of four donors. (B) Human CD14  +   monocytes were stimulated 
in the presence of peptidoglycan or PGE2 for 24 h. IL-1      and IL-23 production was assessed in cell-free supernatants. Results from four independent 
donors are shown. (C) Human naive CD4  +   T cells were co-cultured with monocytes (1:1), activated with anti-CD3 antibody, and cultured for 11 d in the 
presence of IL-23, IL-1     , and/or PGE2. IL-17 production in cell-free supernatants of T cells restimulated for 48 h was measured by ELISA. Results from fi  ve 
independent donors are shown.     540 PGE2 MODULATES THE IL-23–TH17 CELL PATHWAY   | Boniface et al. 
could respond to PGE2.   Consistent with their Th17 memory 
phenotype, PGE2 stimulation did not further enhance the 
percentage of IL-23R  –  positive cells or the level of IL-23R 
expression (  Fig. 7 B  ). However, PGE2 did up-regulate the 
expression of the   IL-1R1   mRNA on the memory T cells 
(  Fig. 7 C  ), and also modulated cytokine production and tran-
scription factor profi  les. The activation of memory T cells 
with IL-1      enhanced IL-17 production, and the combination 
of both IL-1      and IL-23 led to a higher IL-17 up-regulation, 
as recently described (  29  ). The presence of PGE2 alone or 
with IL-23 did not enhance IL-17 production in most donors 
(  Fig. 7 D  ). However, PGE2 enhanced IL-17 production in-
duced by IL-1      and the combination of PGE2, IL-1     , and 
IL-23 induced an even stronger IL-17 up-regulation that cor-
related with enhanced expression of   ROR    t   (  Fig. 7 E  ). Inter-
estingly even PGE2 alone induced   ROR    t   expression, but 
not IL-17 production. Similar results were recently described 
for TGF-      (  30  ), and are consistent with the requirements for 
additional (transcription) factors to fully induce IL-17 pro-
duction. Similar to naive T cells, PGE2 down-regulated IFN-     , 
  T-bet  , and IL-10 expression by activated memory T cells cul-
tured without cytokines or with IL-1      or IL-23 (  Fig. 4, F  –  H  ). 
Furthermore, PGE2 inhibited IFN-     , IL-10, and   T-bet   ex-
pression even in the presence of both IL-1      and IL-23 (  Fig. 4, 
F  –  H  ). Thus PGE2 will not only aff  ect the phenotype and 
function of diff  erentiating Th17 cells but also the function of 
mature eff  ector Th17 cells. 
(  Fig. 5 F  ). Both IL-17  +   IFN-       +   and IL-17  +   IFN-              T cells 
were present at similar percentages in the CCR6  +   T cell pop-
ulation, whereas the CCR6         T cell fraction contained pre-
dominantly IFN-      only producers (  Fig. 5 G  ). The CCR6  +   T 
cells also expressed higher levels of the other Th17 cytokines 
IL-17F, IL-22, CCL20, as well as of   IL-23R   and   ROR    t   
transcripts (  Fig. 5, H and I  ). A similar Th17 profi  le was ob-
served in sorted CCR6  +   T cells isolated from IL-23  –  IL-1       –
  driven Th17 cells in the absence of PGE2 (  Fig. 6, A and B  ).   
Strikingly, CCR6  +   T cells from IL-23  –  IL-1       –  treated cells in 
the presence of PGE2 expressed higher levels of all these 
Th17 markers (  Fig. 6 B  ). Interestingly, the proportion of 
IL-17  +  , IL-17  +  /IFN-       +  , but not IFN-       +    –  producing cells, was 
increased in IL-23  –  IL-1       –  PGE2 cultures (  Fig. 6 A  ), demon-
strating that PGE2 not only quantitatively enhanced the 
number of IL-17 producers but also increased their intrinsic 
capacity to produce IL-17. Collectively, these data indicate 
that PGE2 also enhanced maturation of Th17 cells. 
  PGE2 regulates memory Th17 cell function 
  As activated/memory T cells constitute a major cell popula-
tion found in infl  amed tissue, we next assessed whether PGE2 
could aff  ect the function of mature Th17 cells in short-term 
cultures. We previously identifi  ed in situ Th17 cells as part of 
the CD4  +  CD45RO  +   memory T cell subset that expresses the 
IL-23R in PBMCs of normal donors (  9  ). Like naive T cells, 
memory T cells mainly expressed   EP2   and   EP4   (  Fig. 7 A  ) and 
  Figure 4.       PGE2 inhibits IL-10 and IFN-     production predominantly via EP4 signaling and cAMP pathways.   Human naive CD4  +   T cells were 
activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-23, IL-1     , PGE2, dibutyryl-cAMP, and/or EP receptor agonists. 
(A  –  C) IL-10 production in cell-free supernatants of T cells restimulated for 48 h. (D  –  F) IFN-      production in cell-free supernatants of T cells restimulated 
for 48 h. (G) Real-time PCR of   T-bet   mRNA expression in T cells after 11 d of culture. Data from six different donors are shown in A and D; horizontal bars 
represent median values. Results in B and E show mean + SEM of three independent experiments. Data in C and F show mean + SEM of fi  ve independent 
experiments. Data in G are representative of two independent experiments. *, P   <   0.05; ***, P   <   0.001.     JEM VOL. 206, March 16, 2009 
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were not detected (  Fig. 8 A  ). The combination of TGF-      
and IL-6 (TGF-       –  IL-6) is crucial for the initial development 
of Th17 cells in mice (  31  –  33  ), whereas IL-1      and IL-23 are 
important for the maturation, expansion, and eff  ector func-
tion of this subset (  24, 34  ). Stimulation of purifi  ed naive 
  PGE2 regulates murine Th17 function 
  We also assessed whether PGE2 could directly aff  ect IL-17 
production from mouse CD4  +   T cells. Similar to human 
cells, murine naive and memory CD4  +   T cells expressed   EP2   
and   EP4   genes, whereas   EP1   and   EP3   mRNA transcripts 
  Figure 5.       CCR6 expression defi  nes Th17 cytokine producers and is up-regulated in the presence of IL-1    , IL-23, and PGE2.   Human  naive 
CD4  +   T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-23, IL-1     , and/or PGE2. (A) Flow cytometric quan-
tifi  cation of CCR6 in CD3  +   CD4 +   T cells restimulated for 48 h. Results are representative of three independent experiments. (  B  –  D  ) Flow cytometric quanti-
fi  cation of CCR6  +   (B),  CCR6 + CCR4 +   (C), or CCR6  + IL-23R +   (D) in CD3  +   CD4 +   T cells restimulated for 48 h. *, P   <   0.05. Results represent mean + SEM of nine 
independent experiments. (E) CD4  + CCR6 +   and  CD4 + CCR6        T cells from IL-1     , IL-23, and PGE2-treated T cells were sorted and added to inserts that were 
placed in wells containing CCL20 or SDF-1     , forming an upper and lower chamber separated by a membrane bearing 5-  μ  m pores. Responding cells that 
migrated to the lower chamber were harvested and counted by fl  ow cytometry. Results represent mean + SEM of two independent donors and are ex-
pressed as the percentage of migration compared with the 100% migration control. (F  –  I) Naive T cells were activated with anti-CD3/CD28/CD2 beads and 
cultured for 11 d in the presence of IL-1     , IL-23, and/or PGE2. After reactivation, CD4  + CCR6 +   and  CD4 + CCR6        T cells were sorted and cultured for 7 d in 
the presence of IL-2. (F and G) Intracellular IL-17 and IFN-      staining after stimulation with PMA/ionomycin. Results from six independent donors are 
shown in F. *, P   <   0.05. Data in G are representative of six independent experiments. (H) Production of IL-17, IL-17F, IL-22, and CCL20 in cell-free superna-
tants of T cells restimulated for 24 h. (I) Real-time PCR analysis of   IL-23R   and   ROR  t   gene expression in T cells restimulated 24 h. Results in H and I are 
representative of four independent experiments.     542 PGE2 MODULATES THE IL-23–TH17 CELL PATHWAY   | Boniface et al. 
duction, particularly in combination with both IL-1      and 
IL-23 (  Fig. 8 B  ).   A similar profi  le was observed with stimula-
tion of purifi  ed CD4  +  CD44  hi  CD62L  lo   memory T cells (  Fig. 
8 B  ). Once again, it is the combination of PGE2, IL-1     , and 
IL-23 that induced the highest level of IL-17 production. 
The eff  ect of PGE2 on IL-10 production by naive and memory 
CD4  +  CD44  lo  CD62L  +   T cells with anti-CD3 and -CD28 
  antibodies in the presence of TGF-       –  IL-6 led to IL-17 pro-
duction, as previously described. Restimulation of these newly 
activated T cells in the presence of IL-1      or IL-23 main-
tained IL-17 production. Furthermore, addition of PGE2 
during this restimulation step greatly enhanced IL-17 pro-
  Figure 6.       PGE2 enhances maturation of Th17 cells.   Human naive CD4  +   T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d 
with IL-1      and -23, in the presence or absence of PGE2. After reactivation, CD4  + CCR6 +   and  CD4 + CCR6        T cells were sorted from both cultures and cul-
tured for 7 d in the presence of IL-2. (A) Intracellular IL-17 and IFN-      staining after stimulation with PMA/Ionomycin. Results from three independent 
donors are shown. (B) Real-time PCR analysis of   IL-17 ,   IL-17F ,   IL-22 ,   CCL20 ,  IL-23R ,   and  ROR  t   in T cells restimulated for 24 h. Results from fi  ve donors 
are shown; horizontal bars represent median values.     JEM VOL. 206, March 16, 2009 
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PGE2, enhanced IL-17 production from memory CD4  +   T 
cells in total human PBMC cultures (  17  ). Here, we specifi  -
cally assessed the PGE2-mediated eff  ects on T cell develop-
ment and function. We showed that PGE2 signals via EP2 
and EP4 receptors and the cAMP–PKA pathway to promote 
human naive T cell diff  erentiation to Th17 cells (proposed 
model in   Fig. 9  ).   PGE2 up-regulated the expression of 
IL-23R and IL-1R on diff  erentiating naive T cells and, in 
combination with Th17-driving cytokines, enhanced STAT3 
phosphorylation and induced a qualitative and quantitative 
shift in function and phenotype toward a strong proinfl  am-
matory/pathogenic Th17 cell. PGE2 enhanced the percent-
age of CCR6-positive, in vitro  –  matured Th17 cells that 
expressed IL-17A, IL-22, IL-17F, CCL20, ROR     t, and 
IL-23R, and it signifi   cantly up-regulated these functional 
markers of the Th17 phenotype (  9, 11, 12  ). This enhanced 
Th17 functionality was also observed when mature CD45RO  +   
memory T cell populations were activated by IL-1      and 
PGE2. Although previous studies have reported that PGE2 
T cells in several mouse strains was also examined. As ex-
pected, activation of these cells in the presence of TGF-       –
  IL-6 induced the production of IL-10, which was inhibited 
by the addition of PGE2 (  Fig. 8 C  ). These results suggest that 
the direct eff  ects of PGE2 on Th17 cells are comparable in 
human and murine biology. 
    DISCUSSION   
  Cyclooxygenase 2 (COX2) inhibitors inhibit prostaglandin 
synthesis, including PGE2, and are used in human to treat 
chronic infl  ammatory diseases such as osteoarthritis, rheuma-
toid arthritis, and ankylosing spondylitis (  35, 36  ). In addition, 
COX2 inhibitors have been shown to reduce the severity of 
experimental autoimmune encephalomyelitis and collagen-
induced arthritis in mice (  37, 38  ). These autoimmune dis-
ease models are associated with exacerbated Th17 responses, 
which are driven by the presence of proinfl  ammatory cyto-
kines such as IL-1 and IL-23 (  13  ) In this context, Chizzolini 
et al. recently reported that another infl  ammatory mediator, 
Figure 7.       PGE2 modulates memory Th17 functions.   (A) Real-time PCR analysis of   EP1 ,   EP2 ,   EP3  , and   EP4   gene expression in human memory CD4  +  
T cells. Mean + SEM of three donors. (B–H) Memory CD4  +   T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 3 d in the presence or 
absence of IL-23, IL-1     , and/or PGE2. (B) Flow cytometric quantifi  cation of IL-23R. Box and whiskers of fi  ve independent experiments are shown. 
(C) Real-time PCR analysis of   IL-1R1   gene expression. Results from four different donors are shown. (D) IL-17 production in cell-free supernatants. 
(E) Real-time PCR of   ROR  t   gene expression. (F) IFN-      production in cell-free supernatants. (G) Real-time PCR of   T-bet   gene expression. (H) IL-10 
production in cell-free supernatants. Data from four (E and G) or nine (D, F, and H) independent donors are shown; horizontal bars represent median 
values. *, P   <   0.05.   544 PGE2 MODULATES THE IL-23–TH17 CELL PATHWAY   | Boniface et al. 
crease in the number of Th17 cells. Furthermore, in addition 
to these direct eff  ects of PGE2 on T cells, PGE2 was also 
  essential for the induction of IL-17 production from naive 
T cells in an APC-dependent manner. We demonstrate that 
PGE2 inhibits IFN-      and IL-10 production by Th17 cells 
and thus regulates their pathogenic potential. The opposing 
eff  ects of PGE2 on increased IL-17 production and reduced 
IFN-      and IL-10 production are mediated by diff  erential 
signaling through EP2 and EP4 receptors, which is unique 
in PGE2 signal transduction (  Fig. 9  ). Finally, we show that 
the PGE2 eff  ects on Th17 function can be extended from 
human to murine biology. Overall, we show that the proin-
fl  ammatory activity of PGE2 is mediated through the IL-23  –
  Th17 pathway. 
  Our results provide new mechanistic insights regarding 
PGE2-mediated signaling in Th17 cells. We show that EP2 
and EP4, but not EP1 or EP3, are the receptors mediating 
PGE2 eff  ects on CD4  +   T cells. In addition, PGE2 activities 
has antiproliferative eff  ects on T cells, we did not observe a 
strong inhibition of proliferation when naive T cells were 
cultured in the presence of IL-23 and IL-1      (unpublished 
data). There are two plausible explanations that may recon-
cile PGE2  ’  s apparent antiproliferative eff   ect and our pro-
Th17 cell development fi  ndings: (a) in the presence of IL-1      
and IL-23, PGE2 may favor the development and/or expan-
sion of Th17 cells, while down-regulating proliferation of 
non-Th17 cells; (b) PGE2 may act on   “  non-Th17 cells  ”   and 
convert them into IL-17 producers, while suppressing overall 
T cell proliferative responses, resulting in an   “  apparent  ”   in-
  Figure 8.       PEG2 regulates murine Th17 cell functions.   (A)  Real-time 
PCR analysis of   EP1 ,   EP2 ,   EP3  , and   EP4   gene expression in purifi  ed mouse 
CD4  +   T cells. Closed triangle symbols represent T cells from draining 
lymph nodes of CFA-primed SJL mice. Open triangle symbols represent 
naive CD4  + CD44 lo CD62L hi   from lymph nodes and spleen of C57BL/6 mice. 
Closed circle symbols represent memory CD4  + CD44 hi CD62L lo   from 
C57BL/6 mice. Open circle symbols represent naive CD4  + CD44 lo CD62L hi  
from BALB/c DO11.10 OVA-TCR transgenic mice. (B, top) FACS-purifi  ed 
naive CD4  +   T cells (CD44  lo CD25 lo  ) from SJL mice were activated with anti-
CD3/CD28 beads in the presence of TGF-      and IL-6 for 3 d. Cells were 
then restimulated for 5 d in the presence of the indicated combinations 
of cytokines with or without PGE2. (B, bottom) Memory CD4  +   T cells (CD-
44  hi CD25 lo  ) were activated with anti-CD3/CD28 beads in the presence of 
cytokines with or without PGE2 for 4 d. IL-17 production in cell-free su-
pernatants was assessed by ELISA and expressed as values normalized to 
the fi  nal number of cells per well. Results are representative of two ex-
periments. (C) Real-time PCR analysis of   IL-10   gene expression in purifi  ed 
mouse CD4  +   T cells. Closed triangle symbols represent T cells from drain-
ing lymph nodes of CFA-primed SJL mice. Cells were cultured for 12 h 
with indicated cytokines with or without PGE2. Cells cultured for 2 d 
showed similar results (not depicted). Open triangles represent naive 
CD4  + CD44 lo CD62L hi   from lymph nodes and spleen of C57BL/6 mice cul-
tured for 1 d. Filled circles represent memory CD4  + CD44 hi CD62L lo   from 
C57BL/6 mice cultured for 1 d. Open circles represent naive 
CD4  + CD44 lo CD62L hi   from BALB/c DO11.10 OVA-TCR transgenic mice cul-
tured for 2 d. SJL and BALB/c data are representative of two experiments/
mouse strain, whereas results from naive and memory C57BL/6 cells are 
from one experiment.     
  Figure 9.       Proposed model for PGE2 effects during Th17 cell devel-
opment.   (A) Binding of PGE2 to EP2 and EP4 enhances intracellular cAMP 
formation and signaling, leading to up-regulation of IL-23R and IL-1R1 
expression, as well as inhibition of the expression of T-bet and production 
of IFN-     . PGE2 binding to EP4 also induces concomitant signaling path-
ways independent of cAMP, such as PI3K or ERK, leading to inhibition of 
IL-10 production. (B) The presence of IL-23, IL-1     , and PGE2 leads to an 
up-regulation of ROR     t, IL-17, and CCR6 expression and inhibition of 
IL-10. Gs, stimulatory guanine nucleotide binding protein.     JEM VOL. 206, March 16, 2009 
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feedback response to suppress immune pathologies (  23, 49  ). 
Indeed, we have previously shown that TGF-      induced IL-10 
production even in the presence of IL-6 and/or IL-23, 
and that IL-10 can restrain the pathogenicity of Th17 cells in 
a mouse model of CNS autoimmune encephalomyelitis (  24  ). 
As shown in this study, human Th17 cells stimulated in 
the presence of IL-1      and/or IL-23 produced IL-10. Thus, 
the ability of PGE2 to strongly inhibit IL-10 production 
is crucial to enhancement of Th17-mediated infl  ammation 
and pathogenicity. 
  PGE2 is also an important regulator of Th1 cells, particularly 
through the inhibition of IFN-      production (  25, 26, 50  ). We 
show here that PGE2 also inhibited IFN-      production by Th17 
cells generated in the presence of IL-1      or IL-23; however, the 
signaling pathways induced by both cytokines prevented this 
inhibition and led to the development of both IL-17  +  /IFN-        , 
as well as IL-17  +  /IFN-       +   producers. These results are in accor-
dance with the phenotype of Th17 cells observed by Chizzolini 
et al. when culturing PBMCs in the presence of IL-23 and 
PGE2 (  17  ). Interestingly, ex vivo Th17 cells producing IL-17 
alone or both IL-17 and IFN-      have been identifi  ed in the 
blood and gut of Crohn  ’  s patients (  8  ). Our results support the 
idea that the presence of IL-23, IL-1     , and PGE2 would lead to 
the development of Th17 cells bearing a phenotype/cytokine 
profi  le close to that found during disease. 
  Our results show that PGE2 directly acts on murine Th17 
cells to enhance IL-17 production. This extends previous 
studies demonstrating that in the mouse system, PGE2  ’  s pro-
Th17 eff  ects were mediated through enhanced DC and mac-
rophage production of IL-23 and IL-1      (  14, 15, 21  ). Hence, 
the mechanisms of PGE2-mediated expansion of pathogenic 
Th17 cells are likely through both T cell  –  dependent and my-
eloid cell  –  dependent pathways. 
  In the mouse culture system, it is well established that the 
combination of TGF-      and IL-6 is necessary and suffi   cient to 
promote both in vitro (and likely in vivo) development of 
IL-17  –  producing CD4  +   T cells. It is important to note that 
IL-6 is a major driver of IL-1R1 and IL-23R in murine T cells. 
Our assessment of PGE2  ’  s infl  uence on murine T cell diff  er-
entiation toward Th17 cells indicated that PGE2 cannot replace 
TGF-      and/or IL-6 for induction of Th17 cells in a 3-d naive 
CD4  +   T cell assay (unpublished data). This was not unexpected, 
as TGF-     /IL-6 can promote 30  –  70% of IL-17  –  producing CD4  +   
T cells in our culture system. PGE2 has more profound ef-
fects on diff  erentiating Th17 cells in our human culture sys-
tem. Although we did not observe a TGF-     /IL-6  –  dependent 
eff  ect on naive human T cells, we found that PGE2 induced 
IL-1R and IL-23R in naive CD4  +   T cells, which enhanced 
the development of Th17 cells induced by IL-23 and IL-1     . 
Although TGF-      is clearly required for the generation of mu-
rine Th17 cells, its role during the development of the human 
counterpart is still controversial. In this regard, Santarlasci 
et al. recently suggested that TGF-      was not critical for human 
Th17 cell development; instead, TGF-      would indirectly 
  favor expansion of Th17 cells through inhibition of Th1 cell 
development (  51  ). 
are likely mediated through the cAMP  –  PKA pathway, as 
the eff  ects of PGE2 can be mimicked in the presence of 
the cAMP analogue dibutyryl cAMP. These fi  ndings are in 
line with the previously reported induction of the cAMP  –
  PKA pathway by EP2 and EP4 (  19, 39  ). Furthermore, we 
show that stimulatory and inhibitory activities of PGE2 on 
cytokine production seem to be mediated by specifi  c PGE2 
receptors, as enhanced IL-17 production is preferentially 
  mediated by EP2 signaling, whereas inhibition of IL-10 and 
IFN-      production occurs mainly through EP4 signaling. 
In addition, the inhibition of IL-10 production induced by 
cAMP was not observed in the presence of IL-1      and IL-23, 
suggesting the induction of additional signaling pathway(s) in 
response to EP4 stimulation. It has been shown that EP4, but 
not EP2, can also induce a concomitant activation of phos-
phatidyl inositol 3 kinase and extracellular signal-regulated 
kinase pathways (  39  ). However, addition of phosphatidyl 
inositol 3 kinase and MAP kinase inhibitors to our cultures 
completely inhibited all cytokine production by T cells 
(unpublished data), so it was not possible to formally test this 
hypothesis. It is of interest to note that PGE2 and the cAMP 
pathway have been shown to up-regulate IL-10 expression 
in monocytic cells through a cAMP-responsive element 
(CRE) in the IL-10 promoter. However, the cAMP-induced 
PKA-dependent phosphorylation of the CRE-binding pro-
tein 1 does not seem to have an important regulatory role in 
T cells, which is also refl  ected by their lack of responsiveness 
to catecholamine-induced, cAMP-dependent IL-10 produc-
tion (  40, 41  ). 
  Human CD4  +   memory T cells producing IL-17 were 
fi  rst identifi  ed from peripheral blood or gut of healthy and 
Crohn  ’  s patients (  8  ), and increasing eff  orts have been made to 
characterize this cell subset. Two groups independently iden-
tifi  ed CCR6 as a chemokine receptor selectively expressed 
on Th17 cells (  8, 18  ). CCR6 is involved in the recruitment 
of pathogenic T cells in multiple sclerosis, rheumatoid arthri-
tis, Crohn  ’  s disease, and psoriasis (  8, 42  –  44  ), and Th17 cells 
are increasingly recognized as crucial mediators of those dis-
eases (  7, 9, 10, 45, 46  ). Therefore, the up-regulated CCR6 
expression in IL-23  –  IL-1       –  PGE2  –  driven Th17 cells is con-
sistent with the generation of cells bearing the phenotype 
of pathogenic effector Th17 cells. In addition, the higher 
  expression of Th17 cytokines in CCR6  +   cells isolated from 
cells treated with a combination of IL-23, IL-1     , and PGE2 
compared with IL-23  –  IL-1       –  treated cells suggest a stronger 
maturation of Th17 cells in the presence of PGE2. It has 
been recently shown that human IL-17  –  producing cells 
are contained within the CD161  +   fraction of circulating or 
tissue-infi  ltrating T cells and that these cells originate from 
CD161  +  CD4  +   T cells of umbilical cord blood (  47  ). Addi-
tional data also suggest that such CD161  +   Th17 cells are 
crucial mediators of intestinal infl  ammation during Crohn  ’  s 
disease (  48  ). 
  IL-10 was originally described as an immunosuppressive 
cytokine produced by Th2 cells. However, it is now recog-
nized that all T cell subsets can produce this cytokine as a 546 PGE2 MODULATES THE IL-23–TH17 CELL PATHWAY   | Boniface et al. 
(BD), and permeabilized and stained with anti  –  IL-17 (eBioscience) and 
anti  –  IFN-      (BD) antibodies using the Cytofi  x/Cytoperm Plus kit (BD). For 
STAT3 phosphorylation analysis, cells were stimulated for 15 min in the 
presence of IL-23. Cells were fi  xed, permeabilized, and stained with anti-
PSTAT3 (tyrosine 705) antibody (BD) following the manufacturer  ’  s instruc-
tions (BD). Data were acquired on a LSR II or a Canto II cytometer and 
analyzed with FlowJo software (Tree Star, Inc.). 
  ELISA and electrochemiluminescence assay.     IL-17F electrochemilu-
minescence assay and IFN-      ELISA were performed as previously de-
scribed (  9  ). Human IL-17, IL-22, CCL20, IL-10, IL-1     , and mouse IL-17 
ELISA kits were obtained from R  &  D Systems. IL-23 electrochemilumines-
cence   assay was developed in-house with biotinylated anti  –  IL-23p19 and 
  –  IL-23p40. The lower limit of quantitation of this assay was 6 pg/ml and had 
no cross-reactivity to IL-12p40 up to 4   μ  g/ml or to IL-12p40/p35 heterodi-
mer up to 5   μ  g/ml, which were the highest concentrations tested. 
  Real-time quantitative PCR.     Real-time quantitative PCR was per-
formed as previously described (  9  ). 
  Statistics.     Wilcoxon signed-rank test or one-way ANOVA (for multiple 
groups) with a Friedman test was used for statistical analysis. P values of 
0.05 or less were considered signifi  cant, and all data are represented as mean + 
the SEM. 
  Online supplemental material.     Fig. S1 depicts the purity of human naive 
CD4  +  CD45RA  +   T cells after isolation. Fig. S2 shows the enhancing eff  ects 
of PGE2 and dibutyryl-cAMP on Th17 cytokines expression in Th17 cells 
polarized in the presence of IL-1      and IL-23. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20082293/DC1. 
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  In conclusion, our study highlights the role of the infl  am-
matory microenvironment as a critical factor in Th17 devel-
opment and regulation. Our fi  ndings also shed light on a 
paradox where the important role of PGE2 in mediating in-
fl  ammation remained controversial in respect to its eff  ects on 
T helper cell function and cytokine production. 
    MATERIALS AND METHODS   
  Human cell cultures.     Buff  y coats were obtained from normal healthy 
  human volunteers participating in the Stanford Medical School Blood Cen-
ter blood donation program in accordance with the Declaration of Helsinki. 
Human protocols were approved by the Schering Plough Institutional Bio-
safety Committee. CD14  +   monocytes were isolated from normal peripheral 
blood using CD14 microbeads (Miltenyi Biotech). Naive CD4  +  CD45RO         T 
cells were isolated and cultured as previously described (  9  ). Memory 
CD4  +  CD45RA         T cells were isolated using the memory T cell isolation kit, 
human (Miltenyi Biotech), according to the manufacturer  ’  s instructions. 
T cells were activated in the presence of beads coated with anti-CD3/
CD28/CD2 antibodies (1 bead:10 cells). For co-culture experiments, mono-
cytes and naive T cells were cultured at a 1:1 ratio in the presence of 0.2   μ  g/ml 
anti-CD3 mAb (Spv-T3b; DNAX). Where indicated, 50 ng/ml hIL-23 
(DNAX), 50 ng/ml hIL-1      (R  &  D Systems), 10   μ  M PGE2 (Sigma-Aldrich), 
10   μ  M butaprost (EP2 agonist), 35   μ  M misoprostol (EP4,EP3  >  EP1  >  EP2 
agonist), 10   μ  M sulprostone (EP1/EP3 agonist; Cayman Chemical), or 100   μ  M 
of dibutyryl-cAMP (Alexis Biochemicals) were added. 
  Mouse cell cultures.     Handling of mice and experimental procedures were 
approved by and conducted in accordance with the Association for As-
sessment and Accreditation of Laboratory Animal Care guidelines of the 
Schering-Plough Biopharma Institutional Animal Care and Use Committee. 
Lymph nodes and spleen cells from naive SJL/J, C57BL/6 (JAX Laboratories), 
or BALB/c DO11.10 OVA TCR transgenic mice (maintained at the Scher-
ing-Plough Biopharma mouse facility) were enriched for CD4  +   cells using 
magnetic purifi  cation (Miltenyi Biotech), according to the manufacturer  ’  s 
instructions. Naive CD4  +  CD44  lo  CD25  lo   and memory CD4  +  CD44  hi  CD25  lo   
T cells were then purifi  ed by FACS. Memory cells were stimulated for 4 d 
with CD3/CD28 T cell expander beads (Dynal) in the presence of diff  er-
ent cytokines (5 ng/ml IL-1     ; 20 ng/ml IL-23) and/or 10   μ  M PGE2. Cells 
were then counted using a Vicell counter and supernatants were analyzed by 
ELISA. Naive cells were cultured for 3 d with CD3/CD28 T cell expander 
beads (Dynal) and 10 ng/ml TGF-      and 100 ng/ml IL-6 (R  &  D Systems). 
Cells were washed and stimulated for an additional 5 d with diff  erent cyto-
kines before cell number was assessed and supernatant cytokine was analyzed 
by ELISA. Cytokine levels are expressed as values normalized to the fi  nal 
number of cells per well. 
  Chemotaxis assays.     Migration assays were performed in 5-  μ  M pore tran-
swells, as previously described (  52, 53  ), using 100 nM CCL20 or 50 nM 
SDF1      (R  &  D Systems). The migration was carried out for 2 h at 37  °  C, and 
then a known number of counting beads was added to each well. Beads and 
cells were easily distinguishable by fl  ow cytometry when plotting side scatter 
versus forward scatter, allowing the determination of the cell/bead ratio. 
The cell/bead ratio obtained from cells added directly to the wells was con-
sidered as 100% migration. 
  Cell sorting.     CD4  +  CCR6  +   and CD4  +  CCR6         cell subsets were purifi  ed by 
cell sorting using anti-CCR6 and -CD4 antibodies (BD). Cell sorting was 
done with a FACSAria instrument (BD). 
  Cell surface receptor and intracellular cytokine staining.     For analysis 
of cell surface proteins, cells were stained with anti-CD4, -CD3, -CD45RA, 
-CCR6, -CCR4 (BD), -EP2, -EP4 (Cayman Chemical), and/or   –  IL-23R 
(BAF1400; R  &  D Systems) antibodies. For intracellular staining, cells were 
stimulated for 5 h with PMA, ionomycin (Sigma-Aldrich), and GolgiStop JEM VOL. 206, March 16, 2009 
ARTICLE
547
        29  .   Liu  ,   H.  , and   C.     Rohowsky-Kochan  .   2008  .   Regulation of IL-17 in hu-
man CCR6+ Eff  ector memory T cells.       J. Immunol.       180  :  7948    –    7957  .   
        30  .   Manel  ,   N.  ,   D.     Unutmaz  , and   D.R.     Littman  .   2008  .   The diff  erentia-
tion of human T(H)-17 cells requires transforming growth factor-beta 
and induction of the nuclear receptor RORgammat.       Nat. Immunol.     
  9  :  641    –    649  .    
        31  .   Bettelli  ,   E.  ,   Y.     Carrier  ,   W.     Gao  ,   T.     Korn  ,   T.B.     Strom  ,   M.     Oukka  ,   H.L.   
  Weiner  , and   V.K.     Kuchroo  .   2006  .   Reciprocal developmental pathways 
for the generation of pathogenic eff  ector TH17 and regulatory T cells.   
    Nature      .     441  :  235    –    238  .    
        32  .   Mangan  ,   P.R.  ,   L.E.     Harrington  ,   D.B.     O  ’  Quinn  ,   W.S.     Helms  ,   D.C.   
  Bullard  ,   C.O.     Elson  ,   R.D.     Hatton  ,   S.M.     Wahl  ,   T.R.     Schoeb  , and   C.T.   
  Weaver  .   2006  .   Transforming growth factor-beta induces development 
of the T(H)17 lineage.       Nature      .     441  :  231    –    234  .    
        33  .   Veldhoen  ,   M.  ,   R.J.     Hocking  ,   C.J.     Atkins  ,   R.M.     Locksley  , and   B.   
  Stockinger  .   2006  .   TGFbeta in the context of an infl  ammatory cyto-
kine milieu supports de novo diff  erentiation of IL-17-producing T cells.   
    Immunity      .     24  :  179    –    189  .    
        34  .   Sutton  ,   C.  ,   C.     Brereton  ,   B.     Keogh  ,   K.H.     Mills  , and   E.C.     Lavelle  .   2006  . 
  A crucial role for interleukin (IL)-1 in the induction of IL-17  –  produc-
ing T cells that mediate autoimmune encephalomyelitis.       J. Exp. Med.     
  203  :  1685    –    1691  .    
        35  .   Frampton  ,   J.E.  , and   G.M.     Keating  .   2007  .   Celecoxib: a review of its use 
in the management of arthritis and acute pain.       Drugs      .     67  :  2433    –    2472  .   
        36  .   Geusens  ,  P.  , and  W.    Lems  .  2008  .  Effi   cacy and tolerability of lumiracoxib, 
a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the manage-
ment of pain and osteoarthritis.       Ther. Clin. Risk Manag      .     4  :  337    –    344  .   
        37  .   Ni  ,   J.  ,   Y.Y.     Shu  ,   Y.N.     Zhu  ,   Y.F.     Fu  ,   W.     Tang  ,   X.G.     Zhong  ,   H.     Wang  , 
  Y.F.     Yang  ,   J.     Ren  ,   M.W.     Wang  , and   J.P.     Zuo  .   2007  .   COX-2 inhibi-
tors ameliorate experimental autoimmune encephalomyelitis through 
modulating IFN-gamma and IL-10 production by inhibiting T-bet 
  expression.       J. Neuroimmunol.       186  :  94    –    103  .    
        38  .   Anderson  ,   G.D.  ,   S.D.     Hauser  ,   K.L.     McGarity  ,   M.E.     Bremer  ,   P.C.   
  Isakson  , and   S.A.     Gregory  .   1996  .   Selective inhibition of cyclooxygenase 
(COX)-2 reverses infl  ammation and expression of COX-2 and inter-
leukin 6 in rat adjuvant arthritis.       J. Clin. Invest.       97  :  2672    –    2679  .    
        39  .   Fujino  ,   H.  ,   S.     Salvi  , and   J.W.     Regan  .   2005  .   Diff  erential regulation of 
phosphorylation of the cAMP response element-binding protein after 
activation of EP2 and EP4 prostanoid receptors by prostaglandin E2.   
    Mol. Pharmacol.       68  :  251    –    259  .   
        40  .   Niho  ,   Y.  ,   H.     Niiro  ,   Y.     Tanaka  ,   H.     Nakashima  , and   T.     Otsuka  .   1998  . 
  Role of IL-10 in the crossregulation of prostaglandins and cytokines in 
monocytes.       Acta Haematol.       99  :  165    –    170  .    
        41  .   Riese  ,   U.  ,   S.     Brenner  ,   W.D.     Docke  ,   S.     Prosch  ,   P.     Reinke  ,   M.     Oppert  , 
  H.D.     Volk  , and   C.     Platzer  .   2000  .   Catecholamines induce IL-10 release 
in patients suff  ering from acute myocardial infarction by transactivat-
ing its promoter in monocytic but not in T-cells.       Mol. Cell. Biochem.     
  212  :  45    –    50  .    
        42  .   Kohler  ,   R.E.  ,   A.C.     Caon  ,   D.O.     Willenborg  ,   I.     Clark-Lewis  , and 
  S.R.     McColl  .   2003  .   A role for macrophage infl  ammatory protein-3 
alpha/CC chemokine ligand 20 in immune priming during T cell-
mediated infl  ammation of the central nervous system.       J. Immunol.     
  170  :  6298    –    6306  .   
        43  .   Ruth  ,   J.H.  ,   S.     Shahrara  ,   C.C.     Park  ,   J.C.     Morel  ,   P.     Kumar  ,   S.     Qin  , and 
  A.E.     Koch  .   2003  .   Role of macrophage infl  ammatory protein-3alpha 
and its ligand CCR6 in rheumatoid arthritis.       Lab. Invest.       83  :  579    –    588  .   
        44  .   Homey  ,   B.  ,   M.C.     Dieu-Nosjean  ,   A.     Wiesenborn  ,   C.     Massacrier  ,   J.J.   
  Pin  ,   E.     Oldham  ,   D.     Catron  ,   M.E.     Buchanan  ,   A.     Muller  ,   R.     deWaal 
Malefyt  ,   et al  .   2000  .   Up-regulation of macrophage infl  ammatory protein-3 
alpha/CCL20 and CC chemokine receptor 6 in psoriasis.       J. Immunol.     
  164  :  6621    –    6632  .   
        45  .   Murphy  ,   C.A.  ,   C.L.     Langrish  ,   Y.     Chen  ,   W.     Blumenschein  ,   T.   
  McClanahan  ,   R.A.     Kastelein  ,   J.D.     Sedgwick  , and   D.J.     Cua  .   2003  . 
  Divergent pro- and antiinfl  ammatory roles for IL-23 and IL-12 in joint 
autoimmune infl  ammation.       J. Exp. Med.       198  :  1951    –    1957  .    
        46  .   Langrish  ,   C.L.  ,   Y.     Chen  ,   W.M.     Blumenschein  ,   J.     Mattson  ,   B.     Basham  , 
  J.D.     Sedgwick  ,   T.     McClanahan  ,   R.A.     Kastelein  , and   D.J.     Cua  .   2005  . 
  IL-23 drives a pathogenic T cell population that induces autoimmune 
infl  ammation.       J. Exp. Med.       201  :  233    –    240  .    
  et al  .   2007  .   Development, cytokine profi  le and function of human in-
terleukin 17-producing helper T cells.       Nat. Immunol.       8  :  950    –    957  .    
        10  .   Hirota  ,   K.  ,   H.     Yoshitomi  ,   M.     Hashimoto  ,   S.     Maeda  ,   S.     Teradaira  ,   N.   
  Sugimoto  ,   T.     Yamaguchi  ,   T.     Nomura  ,   H.     Ito  ,   T.     Nakamura  ,   et al  . 
  2007  .   Preferential recruitment of CCR6-expressing Th17 cells to in-
fl  amed joints via CCL20 in rheumatoid arthritis and its animal model.   
    J. Exp. Med.       204  :  2803    –    2812  .    
        11  .   Acosta-Rodriguez  ,   E.V.  ,   G.     Napolitani  ,   A.     Lanzavecchia  , and   F.   
  Sallusto  .   2007  .   Interleukins 1beta and 6 but not transforming growth 
factor-beta are essential for the diff  erentiation of interleukin 17-produc-
ing human T helper cells.       Nat. Immunol.       8  :  942    –    949  .    
        12  .   Chen  ,   Z.  ,   C.M.     Tato  ,   L.     Muul  ,   A.     Laurence  , and   J.J.     O  ’  Shea  .   2007  . 
  Distinct regulation of interleukin-17 in human T helper lymphocytes.   
    Arthritis Rheum.       56  :  2936    –    2946  .    
        13  .   McGeachy  ,   M.J.  , and   D.J.     Cua  .   2007  .   The link between IL-23 and 
Th17 cell-mediated immune pathologies.       Semin. Immunol.       19  :  372    –    376  .     
        14  .   Sheibanie  ,   A.F.  ,   T.     Khayrullina  ,   F.F.     Safadi  , and   D.     Ganea  .   2007  . 
  Prostaglandin E2 exacerbates collagen-induced arthritis in mice through 
the infl  ammatory interleukin-23/interleukin-17 axis.       Arthritis Rheum.     
  56  :  2608    –    2619  .    
        15  .   Sheibanie  ,   A.F.  ,   J.H.     Yen  ,   T.     Khayrullina  ,   F.     Emig  ,   M.     Zhang  ,   R.   
  Tuma  , and   D.     Ganea  .   2007  .   The proinfl  ammatory eff  ect of prostaglan-
din E2 in experimental infl  ammatory bowel disease is mediated through 
the IL-23  →  IL-17 axis.       J. Immunol.       178  :  8138    –    8147  .   
        16  .   Sheibanie  ,   A.F.  ,   I.     Tadmori  ,   H.     Jing  ,   E.     Vassiliou  , and   D.     Ganea  .   2004  . 
  Prostaglandin E2 induces IL-23 production in bone marrow-derived 
dendritic cells.       FASEB J.       18  :  1318    –    1320  .   
        17  .   Chizzolini  ,   C.  ,   R.     Chicheportiche  ,   M.     Alvarez  ,   C.     de Rham  ,   P.     Roux-
Lombard  ,   S.     Ferrari-Lacraz  , and   J.M.     Dayer  .   2008  .   Prostaglandin E2 
(PGE2) synergistically with interleukin-23 (IL-23) favors human Th17 
expansion.       Blood.       112  :  3696    –    3703  .    
        18  .   Acosta-Rodriguez  ,   E.V.  ,   L.     Rivino  ,   J.     Geginat  ,   D.     Jarrossay  ,   M.   
  Gattorno  ,   A.     Lanzavecchia  ,   F.     Sallusto  , and   G.     Napolitani  .   2007  .   Surface 
phenotype and antigenic specifi  city of human interleukin 17-producing 
T helper memory cells.       Nat. Immunol.       8  :  639    –    646  .    
        19  .   Regan  ,   J.W.     2003  .   EP2 and EP4 prostanoid receptor signaling.       Life Sci.     
  74  :  143    –    153  .    
        20  .   Ivanov  ,   I.I.  ,   B.S.     McKenzie  ,   L.     Zhou  ,   C.E.     Tadokoro  ,   A.     Lepelley  ,   J.J.   
  Lafaille  ,   D.J.     Cua  , and   D.R.     Littman  .   2006  .   The orphan nuclear recep-
tor RORgammat directs the diff  erentiation program of proinfl  amma-
tory IL-17+ T helper cells.       Cell      .     126  :  1121    –    1133  .    
        21  .   Khayrullina  ,   T.  ,   J.H.     Yen  ,   H.     Jing  , and   D.     Ganea  .   2008  .   In vitro dif-
ferentiation of dendritic cells in the presence of prostaglandin E2 alters 
the IL-12/IL-23 balance and promotes diff  erentiation of Th17 cells.   
    J. Immunol.       181  :  721    –    735  .   
        22  .   Lehner  ,   M.  ,   A.     Stilper  ,   P.     Morhart  , and   W.     Holter  .   2008  .   Plasticity 
of dendritic cell function in response to prostaglandin E2 (PGE2) and 
interferon-gamma (IFN-gamma).       J. Leukoc. Biol.       83  :  883    –    893  .    
        23  .   Jankovic  ,   D.  , and   G.     Trinchieri  .   2007  .   IL-10 or not IL-10: that is the 
question.       Nat. Immunol.       8  :  1281    –    1283  .    
        24  .   McGeachy  ,   M.J.  ,   K.S.     Bak-Jensen  ,   Y.     Chen  ,   C.M.     Tato  ,   W.   
  Blumenschein  ,   T.     McClanahan  , and   D.J.     Cua  .   2007  .   TGF-beta and IL-6 
drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 
cell-mediated pathology.       Nat. Immunol.       8  :  1390    –    1397  .    
        25  .   Snijdewint  ,   F.G.  ,   P.     Kalinski  ,   E.A.     Wierenga  ,   J.D.     Bos  , and   M.L.   
  Kapsenberg  .   1993  .   Prostaglandin E2 diff  erentially modulates cytokine 
secretion profi  les of human T helper lymphocytes.       J. Immunol.       150  :
  5321    –    5329  .   
        26  .   Katamura  ,   K.  ,   N.     Shintaku  ,   Y.     Yamauchi  ,   T.     Fukui  ,   Y.     Ohshima  ,   M.   
  Mayumi  , and   K.     Furusho  .   1995  .   Prostaglandin E2 at priming of naive 
CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and 
IL-2, but not IL-4 and IL-5.       J. Immunol.       155  :  4604    –    4612  .   
        27  .   Hilkens  ,   C.M.  ,   A.     Snijders  ,   F.G.     Snijdewint  ,   E.A.     Wierenga  , and   M.L.   
  Kapsenberg  .   1996  .   Modulation of T-cell cytokine secretion by acces-
sory cell-derived products.       Eur. Respir. J. Suppl.       22  :  90s    –    94s  .   
        28  .   Oppmann  ,   B.  ,   R.     Lesley  ,   B.     Blom  ,   J.C.     Timans  ,   Y.     Xu  ,   B.     Hunte  ,   F.   
  Vega  ,   N.     Yu  ,   J.     Wang  ,   K.     Singh  ,   et al  .   2000  .   Novel p19 protein engages 
IL-12p40 to form a cytokine, IL-23, with biological activities similar as 
well as distinct from IL-12.       Immunity      .     13  :  715    –    725  .    548 PGE2 MODULATES THE IL-23–TH17 CELL PATHWAY   | Boniface et al. 
        47  .   Cosmi  ,   L.  ,   R.     De Palma  ,   V.     Santarlasci  ,   L.     Maggi  ,   M.     Capone  ,   F.   
  Frosali  ,   G.     Rodolico  ,   V.     Querci  ,   G.     Abbate  ,   R.     Angeli  ,   et al  .   2008  . 
  Human interleukin 17-producing cells originate from a CD161+CD4+ 
T cell precursor.       J. Exp. Med.       205  :  1903    –    1916  .    
        48  .   Kleinschek  ,   M.A.  ,   K.     Boniface  ,   S.     Sadekova  ,   J.     Grein  ,   E.E.     Murphy  , 
  S.P.     Turner  ,   L.     Raskin  ,   B.     Desai  ,   W.A.     Faubion  ,   R.     de Waal 
Malefyt  ,   et al  .   2009  .   Circulating and gut-resident human Th17 cells 
express CD161 and promote intestinal infl  ammation.       J. Exp. Med.      
In press  .   
        49  .   Li  ,   M.O.  , and   R.A.     Flavell  .   2008  .   Contextual regulation of infl  amma-
tion: a duet by transforming growth factor-beta and interleukin-10.   
    Immunity      .     28  :  468    –    476  .    
        50  .   Kuroda  ,   E.  ,   T.     Sugiura  ,   K.     Zeki  ,   Y.     Yoshida  , and   U.     Yamashita  .   2000  . 
  Sensitivity diff  erence to the suppressive eff  ect of prostaglandin E2 among 
mouse strains: a possible mechanism to polarize Th2 type response in 
BALB/c mice.       J. Immunol.       164  :  2386    –    2395  .   
        51  .   Santarlasci  ,   V.  ,   L.     Maggi  ,   M.     Capone  ,   F.     Frosali  ,   V.     Querci  ,   R.     De 
Palma  ,  F.    Liotta  ,  L.    Cosmi  ,  E.    Maggi  ,  S.    Romagnani  , and  F.    Annunziato  . 
  2009  .   TGF-beta indirectly favors the development of human Th17 cells 
by inhibiting Th1 cells.       Eur. J. Immunol.       39  :  207    –    215  .    
        52  .   Campbell  ,   J.J.  ,   S.     Qin  ,   K.B.     Bacon  ,   C.R.     Mackay  , and   E.C.     Butcher  . 
  1996  .   Biology of chemokine and classical chemoattractant receptors: 
diff  erential requirements for adhesion-triggering versus chemotactic 
  responses in lymphoid cells.       J. Cell Biol.       134  :  255    –    266  .    
        53  .   Bowman  ,   E.P.  ,   J.J.     Campbell  ,   D.     Soler  ,   Z.     Dong  ,   N.     Manlongat  , 
  D.     Picarella  ,   R.R.     Hardy  , and   E.C.     Butcher  .   2000  .   Developmental 
switches in chemokine response profi  les during B cell diff  erentiation 
and maturation.       J. Exp. Med.       191  :  1303    –    1318  .                          